PERAMIVIR
| Brand name | RAPIVAB |
|---|---|
| Active ingredient | PERAMIVIR |
| Strength | 200MG/20ML (10MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | December 2014 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8778997 | May 2027 | use U-3069 |
| 10391075 | February 2027 | use U-3069 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.